1.Kane, JM, Correll, CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010; 79(9): 1115–1124.
2.Faries, DE, Ascher-Svanum, H, Nyhuis, AW, Kinon, BJ. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009; 9: 54.
3.Covell, NH, Jackson, CT, Evans, AC, Essock, SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002; 28(1): 17–29.
4.Weiden, PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007; 68(Suppl 4): 34–39.
5.Weiden, PJ, Buckley, PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of “switching” medications. J Clin Psychiatry. 2007; 68(Suppl 6): 14–23.
6.Weiden, PJ, Aquila, R, Dalheim, L, Standard, JM. Switching antipsychotic medications. J Clin Psychiatry. 1997; 58(Suppl 10): 63–72.
7.Weiden, PJ. Switching in the era of atypical antipsychotics: an updated review. Postgrad Med. 2006; Spec No: 27–44.
8.Correll, CU. Real life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006; 67(1): 160–161.
9.Buckley, PF, Correll, CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008; 69(Suppl 1): 4–17.
12.Sunovion Pharmaceuticals Canada Inc. Sunovion Pharmaceuticals Canada Inc. announces Health Canada approval of once-daily LATUDA™ (lurasidone HCl) for the treatment of patients with schizophrenia. Press release, June 15, 2012. Available at: http://www.sunovion.ca/news/pressReleases/20120615.pdf. Accessed September 6, 2013. 13.Sunovion Pharmaceuticals Canada Inc. Latuda: Product monograph for Latuda (lurasidone HCl) 40 mg, 80 mg and 120 mg film-coated tablets. July 24, 2013. Available at: http://www.sunovion.ca/monographs/latuda.pdf. Accessed September 6, 2013.
14.Citrome, L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011; 65(2): 189–210.
15.Citrome, L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012; 29(10): 815–825.
16.McEvoy, JP, Citrome, L, Hernandez, D, etal. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013; 74(2): 170–179.
17.Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 45(S212): 11–19.
18.Barnes, TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154(5): 672–676.
19.Munetz, MR, Benjamin, S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988; 39(11): 1172–1177.
20.Kay, SR, Opler, LA, Fiszbein, A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems; 1994.
21. Guy W. EDCEU Assessment Manual for Psychopharmacology—Revised (DHEW Publ No ADM 76-338). Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:534–537.
22.Addington, D, Addington, J, Schissel, B. A depression rating scale for schizophrenics. Schizophr Res. 1990; 3(4): 247–251.
23.Posner, K, Brown, GK, Stanley, B, etal. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12): 1266–1277.
24.Browne, G, Gafni, A, Roberts, J, Hoxby, H. Approach to the measurement of costs (expenditures) when evaluating the efficiency of health and social programmes. Working Paper Series 92-12, System-Linked Research Unit. Hamilton, Ontario: McMaster University.
25.Voruganti, L, Awad, A. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002; 56(1–2): 37–46.
26.Ware, J Jr, Kosinski, M, Keller, SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3): 220–233.
27.Vernon, MK, Revicki, DA, Awad, AG, etal. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010; 118(1–3): 271–278.
28.Ogasa, M, Kimura, T, Nakamura, M, Guarino, J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013; 225(3): 519–530.
29.Nakamura, M, Ogasa, M, Guarino, J, etal. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(6): 829–836.
30.Stahl, SM, Cucchiaro, J, Simonelli, D, etal. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013; 74(5): 507–515.
31.Silva, R, Correll, CU, Simonelli, S, etal. Long-term safety and effectiveness of lurasidone in schizophrenia: results of a 22 month, open-label extension study. Poster NR6-37, 165th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 5–9, 2012.
32.Loebel, A, Cucchiaro, J, Xu, J, etal. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147(1): 95–102.
33.Citrome, L, Cucchiaro, J, Sarma, K, etal. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165–176.
34.Leucht, S, Cipriani, A, Spineli, L, etal. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962.
35.De Hert, M, Yu, W, Detraux, J, etal. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012; 26(9): 733–759.